Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy
Public ClinicalTrials.gov record NCT00306150. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients With Bladder Cancer Undergoing Radical or Total Cystectomy.
Study identification
- NCT ID
- NCT00306150
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 57 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Trasylol (Aprotinin, BAYA0128) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2005
- Primary completion
- Not listed
- Completion
- Feb 28, 2007
- Last update posted
- Dec 16, 2014
2005 – 2007
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Denver | Colorado | 80262 | — |
| Not listed | Miami | Florida | 33125 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Portland | Maine | 04102 | — |
| Not listed | Baltimore | Maryland | 21224 | — |
| Not listed | Ann Arbor | Michigan | 48109-0330 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Chapel Hill | North Carolina | 27599-7065 | — |
| Not listed | Cleveland | Ohio | 44106-2602 | — |
| Not listed | Columbus | Ohio | 43214-1419 | — |
| Not listed | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Pittsburgh | Pennsylvania | 15213-2592 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Burlington | Vermont | 05401-1420 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00306150, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2014 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00306150 live on ClinicalTrials.gov.